Biotech

R&D

Prediction is very difficult, especially if it’s about the f...

In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Carl Hansen, CEO of AbCellera, for a conversation on the discovery and acceleration of antibody therapeutics.

News

DISCO dances out of the shadows with €20m for ‘surfaceome’

Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its

R&D

5 changes underway for R&D IT shifting to advanced modalitie...

Back in 2000, the FDA approved only six biologics versus 27 new molecular entities (NMEs).

Digital

A look back at 2023: A Benchling biotech breakfast

As we enter the New Year, and set forth into the myriad possibilities and plans of 2024, it pays to pause and reflect.

News

Spyre raises $180m to advance IBD antibody pipeline

At the start of this year, Aeglea BioTherapeutics was looking like it may go out of business.

News

Start-up Cradle tucks in $24m for protein engineering AI

Dutch-Swiss start-up Cradle has raised €22 million ($24 million) in first-round financing to develop its generative artificial intelligence (GenAI) and synthetic biology p

Prediction is very difficult, especially if it’s about the f...

DISCO dances out of the shadows with €20m for ‘surfaceome’

5 changes underway for R&D IT shifting to advanced modalitie...

A look back at 2023: A Benchling biotech breakfast

Spyre raises $180m to advance IBD antibody pipeline

Start-up Cradle tucks in $24m for protein engineering AI

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Biotech

Editor's Picks